早期承認後の薬剤の有効性を確認する際の課題
Holly Fernandez Lynch1, Christopher T Robertson2
1University of Pennsylvania, Philadelphia, PA, USA.
Science (New York, N.Y.)
|December 2, 2021
まとめ
薬剤改革には 有意義な承認後の試験が不可欠です 市場公開後の重要な研究がいつ,どのように効果的に実施されるのかについて明確化が必要です.
科学分野:
- 薬物開発と規制
- 臨床試験の設計
- 販売後の監視
背景:
- 薬剤の長期的安全性と有効性を評価するには,承認後の試験が不可欠です.
- 現在の規制の枠組みでは,有意義な承認後の研究の実施について,十分な明確性が欠けている可能性があります.
- 市場投入後の臨床試験の価値と実現性を確保することは,医薬品改革の重要な課題です.
研究 の 目的:
- 有意義な承認後の試験を実施できる条件を検証する.
- 市場公開後の臨床試験の設計と実施に関する重要な考慮事項を特定する.
- 規制改革における承認後の試験の役割と実現可能性について明確にする.
主な方法:
- 承認後の研究に関する既存の規制ガイドラインのレビュー
- 販売後の試験の実施に関するケーススタディの分析
- 承認後の試験設計のベストプラクティスに関する専門家の意見のまとめ
主要な成果:
- 有意義な承認後の試験には,明確な目標と堅固な方法論が必要です.
- 市場公開後の試験のタイミングと実行可能性は,特定の薬の特性と治療領域に依存します.
- 効果的な改革には,承認後の価値ある研究の実施を妨げるのではなく,支援する枠組みが必要です.
結論:
- 有意義な承認後の試験を達成するには,その目的,タイミング,方法論的要件を明確に理解する必要があります.
- 規制の明確さは,市場公開後の試験の成功を促進するために極めて重要です.
- 将来の改革では,可行で有力な承認後の試験設計の統合を優先すべきです.
関連する概念動画
01:11Clinical Trials: Overview
3.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.7K
01:25Drug Regulation
2.0K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.0K
01:19Pharmacovigilance
1.1K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.1K
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
12
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
12
01:26FDA Approved Drugs: Changes to Approved Drugs
12
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
12
01:19Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
16
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
16